WIRB-Copernicus Group to Host Webinar on the Challenges of Providing Early Access to Investigational Drugs
Speakers include Chimerix President and CEO M. Michelle Berrey, M.D., M.P.H. and Noted Ethicist Arthur L. Caplan, Ph.D.
PRINCETON, N.J., Oct. 7, 2014 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced that it will be hosting a webinar entitled, “Early Access to Investigational Drugs: Lessons from Ebola,” at 3:00 p.m. EDT today.
Speakers include industry leaders Arthur L. Caplan, Ph.D., head of the Division of Bioethics and Drs. William F. and Virginia Connolly Mitty professor at New York University Langone Medical Center, and M. Michelle Berrey, M.D., M.P.H., president and chief executive officer of Chimerix, Inc., a North Carolina-based biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need.
During this webinar, moderated by Lindsay McNair, M.D., M.P.H., M.S.B., WCG’s chief medical officer, and president of consulting services, speakers will review the regulatory framework that governs the use of investigational drugs outside clinical trials (formerly called “compassionate use”), and will discuss the ethical challenges of responding to these complicated situations.
“The current Ebola outbreak underscores the urgency and importance of helping pharmaceutical and biotechnology companies to speed potentially life-saving therapies to market, but to do so in a manner consistent with the highest standards of ethics and science,” said WCG Chairman and CEO Donald A. Deieso, Ph.D.
This webinar will last approximately one hour and is complimentary for those who wish to attend.
To register for WCG webinar, please visit: https://goto.webcasts.com/starthere.jsp?ei=1043224.
About The WIRB-‐Copernicus Group
The WIRB-Copernicus Group (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG’s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.
WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.
For more information, please visit www.wcgclinical.com.
Download the Press Release